Scientists uncovered how childhood BK virus infections may set off cancer-causing mutations decades later: by activating a ...

A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...

Providing surgeons feedback and education on their performance significantly improved the quality of bladder cancer ...

ImmunityBio recently reported that the European Medicines Agency recommended granting conditional marketing authorization for ANKTIVA, in combination with BCG, to treat BCG-unresponsive non-muscle ...

Recognizing common bladder cancer symptoms, such as blood in urine, can help you identify this disease in its early stages, when it may be more treatable.

EMA recommends conditional authorization for ImmunityBio's Anktiva with BCG after a 71% complete response rate in ...

Tackling a common childhood virus could open the door to preventing bladder cancer, according to new research.

The recommendation addresses a long-standing treatment gap for patients facing bladder removal after standard therapy fails.

Researchers in the United Kingdom have found a common childhood virus that can trigger DNA damage leading to bladder cancer ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...

Shares of ImmunityBio ticked higher after the company said the European Medicines Agency recommended granting a conditional marketing authorization for its treatment for non-muscle invasive bladder ...